Epitopes in Vivo -Derived CD8 T Cell Listeria Monocytogenes Dynamic

Total Page:16

File Type:pdf, Size:1020Kb

Epitopes in Vivo -Derived CD8 T Cell Listeria Monocytogenes Dynamic Dynamic Antigen Presentation Patterns of Listeria monocytogenes-Derived CD8 T Cell Epitopes In Vivo This information is current as Mojca Skoberne, Rafaela Holtappels, Herbert Hof and of September 28, 2021. Gernot Geginat J Immunol 2001; 167:2209-2218; ; doi: 10.4049/jimmunol.167.4.2209 http://www.jimmunol.org/content/167/4/2209 Downloaded from References This article cites 41 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/167/4/2209.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Dynamic Antigen Presentation Patterns of Listeria monocytogenes-Derived CD8 T Cell Epitopes In Vivo1 Mojca S˘koberne,* Rafaela Holtappels,† Herbert Hof,* and Gernot Geginat2* Little information exists regarding the presentation of antigenic peptides in infected tissues. In this study the in vivo presentation of four different CD8 T cell epitopes of Listeria monocytogenes was monitored. Peptide presentation was measured by a new, highly sensitive, ex vivo Ag presentation assay that was based on the testing of freshly isolated cells from infected spleens with peptide- specific CD8 T cell lines in an IFN-␥-specific ELISPOT assay. Remarkably, the peptide presentation pattern of splenocytes and that of macrophages purified from spleens of L. monocytogenes-infected mice were different from those of in vitro infected macrophage-like cell lines. The in vivo Ag presentation pattern of splenocytes also exhibited dynamic changes during the first 48 h of infection. In vivo peptide presentation at later time points postinfection was biased toward immunodominant CD8 T cell epitopes, while at an early time point, 6 h postinfection, subdominant and dominant CD8 T cell epitopes were presented with Downloaded from similar strength. In summary, our studies show that Ag presentation during an infection is a highly dynamic process that only can be fully appreciated by the study of cells infected in their physiological environment. The Journal of Immunology, 2001, 167: 2209–2218. he host response against infection with a complex micro- reticulum (6) or the modulation of the immunogenicity of T cell organism comprises T cells specific for a multitude of Ag by variations in the sequences flanking a T cell epitope (7, 8). http://www.jimmunol.org/ T different antigenic peptides. Generally, the magnitude of The murine infection with Listeria monocytogenes is one of the the T cell response against different antigenic peptides exhibits a infection models where the mechanisms governing CD8 T cell remarkably constant hierarchy, and the majority of the responding induction and expansion were studied in detail. Mice infected with T cells are directed against few immunodominant T cell epitopes L. monocytogenes mount MHC class I Kd-restricted CD8 T cell (1). Numerous studies in different infectious disease model sys- responses against peptides encompassing aa 91–99 of listeriolysin tems revealed that the strength of the CD8 T cell response against O (LLO)3 (4); aa 217–225 (9), 449–457 (10), and 476–484 (11) a peptide is the result of the complex interplay of three major of the p60 protein; and aa 84–92 of the listerial metalloprotease factors: the quantity and stability of peptide MHC class I/com- (12), respectively. In vivo the majority of CD8 T cells are specific by guest on September 28, 2021 plexes expressed on APC, the TCR repertoire of the responding T for the immunodominant epitopes LLO91–99 and p60217–225, while cell population, and the suppression of T cells specific for sub- relatively few T cells are directed against the subdominant dominant epitopes by T cells specific for immunodominant epitopes p60449–457 and Mpl84–92 (13). The frequency of epitopes (reviewed in Ref. 2). Ag presentation is certainly required p60476–484-specific CD8 T cells is intermediate between the fre- for the induction and expansion of CD8 T cells. However, only a quency of p60217–225 and that of p60449–457-specific T cells (11). few studies exist about the processing and presentation of anti- Remarkably, among these four L. monocytogenes-derived peptides genic peptides in vivo. In principle, the extraction and quantifica- the immunodominant LLO91–99 is the least abundant endog- tion of naturally processed antigenic peptides allow the direct anal- enously processed peptide in infected cell lines, while the sub- ysis of Ag processing in tissues (3). Due to the relatively large dominant p60449–457 is the most abundant antigenic peptide in number of infected cells required for this method the extraction of infected cell lines (14). Thus, a paradoxical inverse correlation antigenic peptides from organs was only successful in a few model exists between the abundance of naturally processed antigenic pep- infections (4, 5). More indirectly, bacteria and viruses that express tides in infected cells and the frequency of peptide-specific CD8 T genetically engineered proteins were used to analyze the effects of cells in vivo. variations in Ag presentation on the strength of the CD8 T cell It must be kept in mind that the quantitative analysis of peptide response in vivo. Examples are the enhanced immunogenicity of processing is based on in vitro infected cells and that it is not preprocessed Ags that are directly targeted into the endoplasmic known to what extent this in vitro model represents the in vivo situation. Therefore, in the current study the presentation of L. *Institut fu¨r Medizinische Mikrobiologie und Hygiene, Fakulta¨t fu¨r Klinische Medi- monocytogenes-derived antigenic peptides was monitored in vivo. zin Mannheim der Universita¨t Heidelberg, Mannheim, Germany; and †Institut fu¨r We used a novel approach for the direct measurement of Ag Virologie, Universita¨t Mainz, Mainz, Germany presentation in tissues that is based on the testing of in vivo-in- Received for publication February 15, 2001. Accepted for publication June 5, 2001. fected cells with peptide-specific CD8 T cell lines in a sensitive The costs of publication of this article were defrayed in part by the payment of page ELISPOT assay. Remarkably, the peptide presentation pattern of charges. This article must therefore be hereby marked advertisement in accordance splenocytes infected with L. monocytogenes in vivo exhibited dy- with 18 U.S.C. Section 1734 solely to indicate this fact. namic changes during the first 48 h of infection. In light of this new 1 This work was supported by Deutsche Forschungsgemeinschaft Grant GE 1081/1-1. M.S. was supported by the Slovenian Ministry of Science and the Medical Faculty of finding the possible correlation between peptide presentation and the University of Ljubljana. in vivo CD8 T cell expansion and function was reevaluated. 2 Address correspondence and reprint requests to Dr. Gernot Geginat, Institut fu¨r Medizinische Mikrobiologie und Hygiene, Fakulta¨t fu¨r Klinische Medizin Mannheim der Universita¨t Heidelberg, Theodor Kutzer Ufer 1-3, 68167 Mannheim, Germany. 3 Abbreviations used in this paper: LLO, listeriolysin O; AcN, acetonitrile; TFA, E-mail address: [email protected] trifluoroacetic acid; p.i., postinfection. Copyright © 2001 by The American Association of Immunologists 0022-1767/01/$02.00 2210 PRESENTATION OF CD8 T CELL EPITOPES IN VIVO Materials and Methods was 0–5 min of 0% B, 5–55 min linear increase to 50% B, 55–63 min Mice and infection of mice linear increase to 100% B, 63–66 min of 100% B, and 66–74 min linear decrease to 0% B. One-minute fractions were collected and stored at Female BALB/cOlaHsd (H-2d) mice were purchased (Harlan-Winkel- Ϫ70°C. mann, Borchen, Germany), kept under conventional conditions and used at Isolation of naturally processed peptides from infected cell lines was 8–10 wk of age. Mice were infected with L. monocytogenes serovar 1/2a performed similarly. Six hours postinfection (p.i.) ϳ1 ϫ 108 adherent L. EGD in 0.2 ml PBS either i.v. or i.p. as indicated. Infectious doses were monocytogenes-infected P388 or J774 cells were washed twice with ice- 1 ϫ 106 and 1 ϫ 103 CFU i.v. for ex vivo peptide presentation experiments cold PBS and harvested with a cell scraper. Cell pellets were disrupted, and T cell induction studies, respectively. Bacteria used for infection were sonicated, and lysed for 30 min in 2 ml 0.5% TFA supplemented with in the logarithmic growth phase. The bacterial concentration was estimated proteinase inhibitors as described above. Subsequently, cell lysates were from the OD at 600 nm. centrifuged 30 min at 20,000 ϫ g, and supernatants were further purified by ultrafiltration using MICROSEP (Pall-Gelman, Dreieich, Germany) ul- APC, in vitro infection of APC, and CD8 T cell lines trafiltration units with a 10-kDa cutoff. The low Mr fraction was further P815 mastocytoma cells were used as targets in the cell-mediated cytotox- fractionated by HPLC as described above. icity assay. For in vitro infection experiments macrophage-like J774A1 ϫ 8 (J774) and P388D1 (P388) cells were used as APC. Approximately 1 10 P388 or J774 cells were infected with L.
Recommended publications
  • "Epitope Mapping: B-Cell Epitopes". In: Encyclopedia of Life Sciences
    Epitope Mapping: B-cell Advanced article Epitopes Article Contents . Introduction GE Morris, Wolfson Centre for Inherited Neuromuscular Disease RJAH Orthopaedic Hospital, . What Is a B-cell Epitope? . Epitope Mapping Methods Oswestry, UK and Keele University, Keele, Staffordshire, UK . Applications Immunoglobulin molecules are folded to present a surface structure complementary to doi: 10.1002/9780470015902.a0002624.pub2 a surface feature on the antigen – the epitope is this feature of the antigen. Epitope mapping is the process of locating the antibody-binding site on the antigen, although the term is also applied more broadly to receptor–ligand interactions unrelated to the immune system. Introduction formed of highly convoluted peptide chains, so that resi- dues that lie close together on the protein surface are often Immunoglobulin molecules are folded in a way that as- far apart in the amino acid sequence (Barlow et al., 1986). sembles sequences from the variable regions of both the Consequently, most epitopes on native, globular proteins heavy and light chains into a surface feature (comprised of are conformation-dependent and they disappear if the up to six complementarity-determining regions (CDRs)) protein is denatured or fragmented. Sometimes, by acci- that is complementary in shape to a surface structure on the dent or design, antibodies are produced against linear antigen. These two surface features, the ‘paratope’ on the (sequential) epitopes that survive denaturation, though antibody and the ‘epitope’ on the antigen, may have a cer- such antibodies usually fail to recognize the native protein. tain amount of flexibility to allow an ‘induced fit’ between The simplest way to find out whether an epitope is confor- them.
    [Show full text]
  • Epstein-Barr Virus Epitope-Major Histocompatibility Complex
    University of Massachusetts Medical School eScholarship@UMMS Open Access Articles Open Access Publications by UMMS Authors 2020-03-17 Epstein-Barr Virus Epitope-Major Histocompatibility Complex Interaction Combined with Convergent Recombination Drives Selection of Diverse T Cell Receptor alpha and beta Repertoires Anna Gil University of Massachusetts Medical School Et al. Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/oapubs Part of the Hemic and Lymphatic Diseases Commons, Immune System Diseases Commons, Immunology and Infectious Disease Commons, Infectious Disease Commons, Microbiology Commons, Virus Diseases Commons, and the Viruses Commons Repository Citation Gil A, Kamga L, Chirravuri-Venkata R, Aslan N, Clark FG, Ghersi D, Luzuriaga K, Selin LK. (2020). Epstein- Barr Virus Epitope-Major Histocompatibility Complex Interaction Combined with Convergent Recombination Drives Selection of Diverse T Cell Receptor alpha and beta Repertoires. Open Access Articles. https://doi.org/10.1128/mBio.00250-20. Retrieved from https://escholarship.umassmed.edu/ oapubs/4191 Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 License. This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. RESEARCH ARTICLE Host-Microbe Biology crossm Epstein-Barr Virus Epitope–Major Histocompatibility Complex Interaction Combined with Convergent Recombination Drives Downloaded from Selection of Diverse T Cell Receptor ␣ and ␤ Repertoires Anna Gil,a Larisa Kamga,b Ramakanth Chirravuri-Venkata,c Nuray Aslan,a Fransenio Clark,a Dario Ghersi,c Katherine Luzuriaga,b Liisa K.
    [Show full text]
  • Epitope Spreading: Lessons from Autoimmune Skin Diseases
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector REVIEW Epitope Spreading: Lessons From Autoimmune Skin Diseases Lawrence S. Chan,*† Carol J. Vanderlugt,‡ Takashi Hashimoto,§ Takeji Nishikawa,¶ John J. Zone,** Martin M. Black,†† Fenella Wojnarowska,‡‡ Seth R. Stevens,§§ Mei Chen,† Janet A. Fairley,¶¶ David T. Woodley,*† Stephen D. Miller,‡ and Kenneth B. Gordon†‡ *Medicine Service, Section of Dermatology, Lakeside Division, VA Chicago Health Care System, Chicago, Illinois, U.S.A.; Departments of †Dermatology and ‡Microbiology and Immunology, Northwestern University Medical School, Chicago, Illinois, U.S.A.; ¶¶Department of Dermatology, Kurume University School of Medicine, Kurume, Japan; ¶Department of Dermatology, Keio University School of Medicine, Tokyo, Japan; **Medicine Service, Section of Dermatology, Salt Lake City VA Medical Center, Salt Lake City, Utah, U.S.A.; ††Department of Dermatopathology, Guy’s and St. Thomas Medical and Dental School, London, U.K.; ‡‡Department of Dermatology, The Oxford Radcliffe Hospital, Oxford, U.K.; §§Department of Dermatology, Case Western Reserve University School of Medicine, Cleveland, Ohio, U.S.A.; ¶¶Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin, U.S.A. Autoimmune diseases are initiated when patients develop In experimental autoimmune animal diseases, ‘‘epitope aberrant T and/or B cell responses against self proteins. spreading’’ seems to have significant physiologic impor- These responses
    [Show full text]
  • A Murine CD8+ T Cell Epitope Identified in the Receptor-Binding
    Article A Murine CD8+ T Cell Epitope Identified in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein Jihyun Yang 1,† , Eunjin Kim 1,2,†, Jong-Soo Lee 2 and Haryoung Poo 1,* 1 Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea; [email protected] (J.Y.); [email protected] (E.K.) 2 Department of Preventive Veterinary Medicine, College of Veterinary Medicine, Chungnam National University, Daejeon 34134, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-42-860-4157 † These authors contributed equally to this study. Abstract: The ongoing COVID-19 pandemic caused by SARS-CoV-2 has posed a devastating threat worldwide. The receptor-binding domain (RBD) of the spike protein is one of the most important antigens for SARS-CoV-2 vaccines, while the analysis of CD8 cytotoxic T lymphocyte activity in preclinical studies using mouse models is critical for evaluating vaccine efficacy. Here, we immunized C57BL/6 wild-type mice and transgenic mice expressing human angiotensin-converting enzyme 2 (ACE2) with the SARS-CoV-2 RBD protein to evaluate the IFN-γ-producing T cells in the splenocytes of the immunized mice using an overlapping peptide pool by an enzyme-linked immunospot assay and flow cytometry. We identified SARS-CoV-2 S395–404 as a major histocompatibility complex (MHC) class I-restricted epitope for the RBD-specific CD8 T cell responses in C57BL/6 mice. Keywords: SARS-CoV-2; cell-mediated immunity; CD8 cytotoxic T lymphocyte; epitope; vaccine Citation: Yang, J.; Kim, E.; Lee, J.-S.; Poo, H.
    [Show full text]
  • Heteroclitic CD8 T Cell Epitopes Enhanced Antiviral Immunity
    Structural and Functional Correlates of Enhanced Antiviral Immunity Generated by Heteroclitic CD8 T Cell Epitopes This information is current as Jonathan A. Trujillo, Stephanie Gras, Kelly-Anne Twist, of September 30, 2021. Nathan P. Croft, Rudragouda Channappanavar, Jamie Rossjohn, Anthony W. Purcell and Stanley Perlman J Immunol 2014; 192:5245-5256; Prepublished online 2 May 2014; doi: 10.4049/jimmunol.1400111 Downloaded from http://www.jimmunol.org/content/192/11/5245 References This article cites 56 articles, 31 of which you can access for free at: http://www.jimmunol.org/content/192/11/5245.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 30, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2014 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Structural and Functional Correlates of Enhanced Antiviral Immunity Generated by Heteroclitic CD8 T Cell Epitopes Jonathan A. Trujillo,*,1 Stephanie Gras,†,1 Kelly-Anne Twist,† Nathan P.
    [Show full text]
  • Epitope Similarity Cannot Explain the Pre-Formed T Cell Immunity
    www.nature.com/scientificreports OPEN Epitope similarity cannot explain the pre‑formed T cell immunity towards structural SARS‑CoV‑2 proteins Ulrik Stervbo 1,2,4*, Sven Rahmann 3,4*, Toralf Roch 1,2, Timm H. Westhof1 & Nina Babel1,2 The current pandemic is caused by the SARS‑CoV‑2 virus and large progress in understanding the pathology of the virus has been made since its emergence in late 2019. Several reports indicate short lasting immunity against endemic coronaviruses, which contrasts studies showing that biobanked venous blood contains T cells reactive to SARS‑CoV‑2 S‑protein even before the outbreak in Wuhan. This suggests a preformed T cell memory towards structural proteins in individuals not exposed to SARS‑CoV‑2. Given the similarity of SARS‑CoV‑2 to other members of the Coronaviridae family, the endemic coronaviruses appear likely candidates to generate this T cell memory. However, given the apparent poor immunological memory created by the endemic coronaviruses, immunity against other common pathogens might ofer an alternative explanation. Here, we utilize a combination of epitope prediction and similarity to common human pathogens to identify potential sources of the SARS‑CoV‑2 T cell memory. Although beta‑coronaviruses are the most likely candidates to explain the pre‑existing SARS‑CoV‑2 reactive T cells in uninfected individuals, the SARS‑CoV‑2 epitopes with the highest similarity to those from beta‑coronaviruses are confned to replication associated proteins—not the host interacting S‑protein. Thus, our study suggests that the observed SARS‑CoV‑2 pre‑formed immunity to structural proteins is not driven by near‑identical epitopes.
    [Show full text]
  • Exploring Epitope and Functional Diversity of Anti-SARS-Cov2 Antibodies Using AI-Based Methods
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.23.424199; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Exploring epitope and functional diversity of anti-SARS-CoV2 antibodies using AI-based methods. Dumet C1., Jullian Y.1, Musnier A.1, Rivière Ph.2, Poirier N.3, Watier H.4, Bourquard T.1, Poupon A.1,5,* 1: MAbSilico SAS, 1 impasse du Palais, 37000 Tours, France. 2: VisionsCarto, France. 3: OSE Immunotherapeutics, Nantes, France. 4: EA7501, Université de Tours, et laboratoire d'immunologie, CHU de Tours. 5: PRC, INRAE, CNRS, Université de Tours, 37380 Nouzilly, France ; Inria, Inria Saclay-Île-de-France, 91120 Palaiseau, France *: corresponding author. Summary Since the beginning of the COVID19 pandemics, an unprecedented research effort has been conducted to analyze the antibody responses in patients, and many trials based on passive immunotherapy — notably monoclonal antibodies — are ongoing. Twenty-one antibodies have entered clinical trials, 6 having reached phase 2/3, phase 3 or having received emergency authorization. These represent only the tip of the iceberg, since many more antibodies have been discovered and represent opportunities either for diagnosis purposes or as drug candidates. The main problem facing laboratories willing to develop such antibodies is the huge task of analyzing them and choosing the best candidate for exhaustive experimental validation. In this work we show how artificial intelligence-based methods can help in analyzing large sets of antibodies in order to determine in a few hours the best candidates in few hours.
    [Show full text]
  • HDX-MS for Epitope Characterization of a Therapeutic ANTIBODY Candidate on the Calcium-Binding Protein Annexin-A1
    antibodies Article HDX-MS for Epitope Characterization of a Therapeutic ANTIBODY Candidate on the Calcium-Binding Protein Annexin-A1 Marius Gramlich 1, Henry C. W. Hays 2, Scott Crichton 2, Philipp D. Kaiser 1, Anne Heine 1, Nicole Schneiderhan-Marra 1, Ulrich Rothbauer 1,3, Dieter Stoll 1,4, Sandra Maier 1 and Anne Zeck 1,* 1 NMI, Natural and Medical Sciences Institute at the University of Tuebingen, Markwiesenstr. 55, 72770 Reutlingen, Germany; [email protected] (M.G.); [email protected] (P.D.K.); [email protected] (A.H.); [email protected] (N.S.-M.); [email protected] (U.R.); [email protected] (D.S.); [email protected] (S.M.) 2 Medannex Ltd., 1 Lochrin Square, Fountainbridge, Edinburgh EH3 9QA, UK; [email protected] (H.C.W.H.); [email protected] (S.C.) 3 Pharmaceutical Biotechnology, Eberhard Karls University Tuebingen, Geschwister-Scholl-Platz, 72074 Tuebingen, Germany 4 Department of Life Sciences, University of Applied Sciences Albstadt-Sigmaringen, Anton-Guentherstr. 51, 72488 Sigmaringen, Germany * Correspondence: [email protected]; Tel.: +49-7121-51530-0; Fax: +49-7121-51530-816 Abstract: Annexin-A1 (ANXA1) belongs to a class of highly homologous Ca2+-dependent phospholipid- binding proteins. Its structure consists of a core region composed of four homologous repeats ar- ranged in a compact, hydrolysis-resistant structure and an N-terminal region with a Ca2+-dependent conformation. ANXA1 is involved in several processes, including cell proliferation, apoptosis, Citation: Gramlich, M.; Hays, metastasis, and the inflammatory response. Therefore, the development of antibodies blocking H.C.W.; Crichton, S.; Kaiser, P.D.; selected regions on ANXA1 holds great potential for the development of novel therapeutics treating Heine, A.; Schneiderhan-Marra, N.; inflammatory and cancer diseases.
    [Show full text]
  • Epitope Recognition in HLA-DR3 Transgenic Mice Immunized to TSH-R Protein Or Peptides Hidefumi Inaba
    University of Rhode Island DigitalCommons@URI Institute for Immunology and Informatics Faculty Institute for Immunology and Informatics (iCubed) Publications 2013 Epitope Recognition in HLA-DR3 Transgenic Mice Immunized to TSH-R Protein or Peptides Hidefumi Inaba Leonard Moise University of Rhode Island See next page for additional authors Follow this and additional works at: https://digitalcommons.uri.edu/immunology_facpubs The University of Rhode Island Faculty have made this article openly available. Please let us know how Open Access to this research benefits oy u. This is a pre-publication author manuscript of the final, published article. Terms of Use This article is made available under the terms and conditions applicable towards Open Access Policy Articles, as set forth in our Terms of Use. Citation/Publisher Attribution Inaba, H., Moise, L., Martin, W., De Groot, A. S., Desrosiers, J., Tassone, R., Buchman, G., Akamizu, T., & De Groot, L. J. (2013). Epitope Recognition in HLA-DR3 Transgenic Mice Immunized to TSH-R Protein or Peptides. Endocrinology, 154(6), 2234-2243. Available at: http://dx.doi.org/10.1210/en.2013-1033 This Article is brought to you for free and open access by the Institute for Immunology and Informatics (iCubed) at DigitalCommons@URI. It has been accepted for inclusion in Institute for Immunology and Informatics Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. Authors Hidefumi Inaba, Leonard Moise, William Martin, Anne S. De Groot, Joe Desrosiers, Ryan Tassone, George Buchman, Takashi Akamizu, and Leslie J. De Groot This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/immunology_facpubs/68 1 Title 2 EPITOPE RECOGNITION IN HLA-DR3 TRANSGENIC MICE IMMUNIZED TO TSH-R 3 PROTEIN OR PEPTIDES 4 5 Hidefumi Inaba, Leonard Moise, William Martin, Anne S.earls De Groot, 6 Joe Desrosiers, Ryan Tassone, George Buchman, Takashi Akamizu, 7 and Leslie J.
    [Show full text]
  • Superactivation of an Immune Response Triggered by Oligomerized T Cell Epitopes
    Proc. Natl. Acad. Sci. USA Vol. 94, pp. 14642–14647, December 1997 Immunology Superactivation of an immune response triggered by oligomerized T cell epitopes OLAF RO¨TZSCHKE,KIRSTEN FALK, AND JACK L. STROMINGER Department of Molecular and Cellular Biology, Harvard University, 7 Divinity Avenue, Cambridge, MA 02138 Contributed by Jack L. Strominger, October 27, 1997 ABSTRACT The peptides bound to class II major histo- ence the immune response by promoting the artificial formation compatibility complex (MHC) molecules extend out both ends of of such clusters. Class II MHC molecules, in contrast to class I the peptide binding groove. This structural feature provided the MHC molecules, do not impose length restrictions on their opportunity to design multivalent polypeptide chains that cross- ligands (2, 11). The peptide is attached to the binding site like a link class II MHC molecules through multiple, repetitive MHC string of rope to a clamp, with both ends extruding from the MHC binding sites. By using recombinant techniques, polypeptide molecule. It was therefore assumed that the formation of antigen- oligomers were constructed that consist of up to 32 copies of an loaded MHC clusters can be achieved simply by allowing multiple HLA-DR1-restricted T cell epitope. The epitope HA306–318, class II MHC molecules to bind to a single multivalent chain of derived from influenza virus hemagglutinin, was connected by peptide antigens. For this purpose, polypeptides were produced 12- to 36-aa long spacer sequences. These oligomers were found that contained multiple copies of a T cell epitope derived from to cross-link soluble HLA-DR1 molecules efficiently and, upon the influenza virus hemagglutinin protein (HA306–318; ref.
    [Show full text]
  • Structure Define Epitope and Paratope Size and Antibody And
    Antibody and Antigen Contact Residues Define Epitope and Paratope Size and Structure This information is current as James W. Stave and Klaus Lindpaintner of September 26, 2021. J Immunol published online 24 June 2013 http://www.jimmunol.org/content/early/2013/06/22/jimmun ol.1203198 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2013/06/24/jimmunol.120319 Material 8.DC1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 26, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published June 24, 2013, doi:10.4049/jimmunol.1203198 The Journal of Immunology Antibody and Antigen Contact Residues Define Epitope and Paratope Size and Structure James W. Stave and Klaus Lindpaintner1 A total of 111 Ag–Ab x-ray crystal structures of large protein Ag epitopes and paratopes were analyzed to inform the process of eliciting or selecting functional and therapeutic Abs.
    [Show full text]
  • Identification of Highly Conserved SARS-Cov-2 Antigenic Epitopes
    viruses Article Identification of Highly Conserved SARS-CoV-2 Antigenic Epitopes with Wide Coverage Using Reverse Vaccinology Approach Yasmin Hisham 1, Yaqoub Ashhab 2 , Sang-Hyun Hwang 3,* and Dong-Eun Kim 1,* 1 Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Korea; [email protected] 2 Palestine-Korea Biotechnology Center, Palestine Polytechnic University, Hebron 90100, Palestine; [email protected] 3 Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea * Correspondence: [email protected] (S.-H.H.); [email protected] (D.-E.K.) Abstract: One of the most effective strategies for eliminating new and emerging infectious diseases is effective immunization. The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) warrants the need for a maximum coverage vaccine. Moreover, mutations that arise within the virus have a significant impact on the vaccination strategy. Here, we built a comprehensive in silico workflow pipeline to identify B-cell- and T-cell-stimulating antigens of SARS-CoV-2 viral proteins. Our in silico reverse vaccinology (RV) approach consisted of two parts: (1) analysis of the selected viral proteins based on annotated cellular location, antigenicity, allele coverage, epitope density, and mutation density and (2) analysis of the various aspects of the epitopes, including Citation: Hisham, Y.; Ashhab, Y.; antigenicity, allele coverage, IFN-γ induction, toxicity, host homology, and site mutational density. Hwang, S.-H.; Kim, D.-E. After performing a mutation analysis based on the contemporary mutational amino acid substitutions Identification of Highly Conserved observed in the viral variants, 13 potential epitopes were selected as subunit vaccine candidates.
    [Show full text]